With the Healthcare Sector in Turmoil Should You Rebalance Your Portfolio? Update-3…C’mon Back Biotech at ASCO!

Update-3 5/22-23..... 10:50a EDT....VIGL  continues to run on Sanofi acquisition.at $8/sh. Should spark our SMID biotech trading list but XBI is stuck at $78. Ahead of ASCO we should see more green shoots among SMID biotechs and soon some major news from oncology players like MERUS N.V.(MRUS)...

Large Cap Biopharmaceutical Update: Mixed Performance as Tariffs Loom…Update-2…4/29…Good gains in pharma and medtech

Update-2..4/29...3p EDT...Novartis (NVS) stock up over 1% on earnings beat raised guidance. Broad pipeline in four therapeutic areas. Good value with FWD PE of 14.9,PS of 4.3, Div.of 3.5%, RSI trending up. Added to stock today. Strong momentum in pharma, medtech, even Pfizer up 4% with 7%...

Pin It on Pinterest